ClinicalTrials.gg
CompletedNCT05165316EULAST-IIUpdated Nov 10, 2026

European Long-acting Antipsychotics in Schizophrenia Trial-II

An observational study in Schizophrenia, sponsored by Rene Kahn. Completed at 1 site in Israel. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-11-10.

Sponsored by Rene Kahn · Observational

How we know

Updated Nov 10, 2026Now CompletedEnrollment updatedGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Study type
Observational
Model
Cohort
Time perspective
Cross-sectional
Enrollment
159
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 112 studies in Schizophrenia with a site in Israel — 3 open to participants now, 4 under way, none of them phase 3. Schizophrenia · Israel.

Enrollment
8th of 22
159 · median 100
Started
2021
with 1 other
Observational
22 of 112
1 open now
Registered
103rd of 112
by date

Among the 112 studies in Schizophrenia with a site in Israel, this one is the 8th largest by enrollment of the 22 observational ones that give a count, is one of 2 that started in 2021, is one of 22 observational ones, and was the 103rd registered.

Schizophrenia

3,574 studies on the registry are indexed under Schizophrenia; 494 are open to participants now.

Browse Schizophrenia studies →

Open to participants now

3 of the 112 studies in Schizophrenia with a site in Israel are open now. Recruiting first, the newest first:

All 3 open studies →

A study can be open while its sites in Israel have not opened yet or have stopped. Only those recruiting at a site in Israel →

Who these studies take

Of the 333 Schizophrenia studies recruiting now, 63 (19%) set no upper age limit and 258 (77%) stop at 75 or younger; 42 take children under 18; 83 take healthy volunteers.

This study: 18 Years and older · all sexes.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 112 studies in Schizophrenia with a site in Israel, or all of them as a file.
02

Study summary

Schizophrenia is a chronic psychiatric illness with a heterogeneous disease course, varying from periods of symptomatic remission to relapse. Relative to the wealth of scientific data on the course of schizophrenia during the two years following the first psychotic episode, the outcome of schizophrenia patients over the first decade of their illness has been studied to a lesser degree. In this follow-up cohort study the aim is to investigate the long-term outcome of schizophrenia patients who participated in the previously conducted EULAST-I clinical trial, in the first decade after being diagnosed.

Read the detailed description

At this point, given the heterogeneity of published studies, it remains unclear if depot medication can reduce relapse rates and improve clinical outcome when offered to all patients in need of continuation treatment with antipsychotics. Before anyone can conclude whether or not all schizophrenia patients could benefit from a switch to depot formulations, several questions remain to be answered. Is depot medication associated with better continuation rates and outcome? How are depot medications tolerated as compared to oral medication? In order to clarify these important issues this study aims to perform a large multi-center trial in which schizophrenia patients in need of continuous treatment who are randomized 1:1:1:1 to two different depot preparations or to two different oral medications; patients will be followed up for a total of 19 months.

The primary objective of this trial is to compare all cause discontinuation rates in patients with schizophrenia randomized to oral antipsychotic medications (i.e., aripiprazole or paliperidone) versus depot antipsychotic medications (i.e., paliperidone palmitate or aripiprazole depot) over an 18 month follow-up period.

03

Conditions studied

  • Schizophrenia

Browse trials for

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Sampling method
Non-probability sample

Study population

The study population will consist of patients with schizophrenia who participated in the previously conducted EULAST-I clinical trial. All patients who were randomized (to either aripiprazole oral, aripiprazole depot, paliperidone oral, paliperidone depot) or who participated in the naturalistic follow-up part of the EULAST-I clinical trial will be invited to participate in the current long-term follow-up cohort study (EULAST-II); this includes patients who dropped-out after randomization, patients who met All Cause Discontinuation (ACD) criteria and patients who completed the previous EULAST-I clinical trial. Patients will be over 18 years of age. The current long-term follow-up visit will take place at least three years after each patient's last visit as conducted within the EULAST-I clinical trial or the naturalistic follow-up study.

Eligibility criteria

Inclusion Criteria:

  1. Capable of providing written / have a legal representative to provide written informed consent. *
  2. Having been randomized to one of the four treatment arms (aripiprazole oral, aripiprazole depot, paliperidone oral, paliperidone depot) in the 2014-002765-30 EULAST-I clinical trial or having participated in the EULAST-I naturalistic cohort study.

    • Unless prohibited by local law (e.g. due to incarceration).

Exclusion Criteria: No exclusion criteria are applicable in this study.

Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

05

Study design

Observational model
Cohort
Time perspective
Cross-sectional
Enrollment
159 participants (actual)
Patient registry
No
06

What researchers measure

Primary outcomes

  1. To assess which baseline EULAST-I clinical trial baseline characteristics predict healthcare utilization (defined as number of days hospitalized) over a period of 3 - 10 years (since the EULAST-I clinical trial baseline visit).

    Time frame: 3 - 10 years (since the EULAST-I clinical trial baseline visit).

Secondary outcomes

  1. To provide insight into long-term social functioning as measured through the Personal and Social Performance (PSP) scale.

    Time frame: 3 - 10 years (since the EULAST-I clinical trial baseline visit).

  2. To provide insight into long-term sociodemographic outcome (living circumstances, education, marital status).

    Time frame: 3 - 10 years (since the EULAST-I clinical trial baseline visit).

  3. To provide insight in changes in neuropsychiatric diagnoses as measured through the Mini-International Neuropsychiatric Interview 7.0.2 (M.I.N.I. 7.0.2) since the EULAST-I clinical trial screening visit.

    Time frame: 3 - 10 years (since the EULAST-I clinical trial baseline visit).

  4. To provide insight in long-term outcome in quality of life as measured through the Euroqol quality of life scale (EQ-5D-5L).

    Time frame: 3 - 10 years (since the EULAST-I clinical trial baseline visit).

  5. To provide insight in long-term outcome in alcohol and drug use as well as smoking as measured through the Alcohol, Smoking and Substance Involvement Screening Test (ASSIST).

    Time frame: 3 - 10 years (since the EULAST-I clinical trial baseline visit).

  6. To provide insight in long-term outcome of tardive dyskinesia as measured through the Abnormal and Involuntary Movement Scale (AIMS).

    Time frame: 3 - 10 years (since the EULAST-I clinical trial baseline visit).

  7. To provide insight in long-term outcome of extrapyramidal symptoms as measured through the St. Hans rating scale.

    Time frame: 3 - 10 years (since the EULAST-I clinical trial baseline visit).

  8. To provide insight in the use of antipsychotic medication and other medication since the previous EULAST-I clinical trial.

    Time frame: 3 - 10 years (since the EULAST-I clinical trial baseline visit).

  9. To provide insight into the reasons for hospitalizations since the baseline visit of the previous EULAST-I clinical trial.

    Time frame: 3 - 10 years (since the EULAST-I clinical trial baseline visit).

  10. To provide insight into the incidence of suicide attempts since the baseline visit of the previous EULAST-I clinical trial

    Time frame: 3 - 10 years (since the EULAST-I clinical trial baseline visit).

07

Study locations

1 site
  • Tel Hashomer The Sheba Medical Center
    Ramat Gan, Israel
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Dec 2021 to primary completion in Feb 2026, 49 months.

How these figures are worked out, and which studies are left out of them.

Registered
Dec 7, 2021
First posted
Dec 21, 2021
StartActual
Dec 31, 2021
Primary completionActual
Feb 13, 2026
CompletionActual
Feb 13, 2026
Last update
Nov 10, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Status
Enrolling by invitation→Completed
changed Nov 10, 2026
Enrollment
400 (estimated)→159 (actual)
Nov 10, 2026
Show all 1 update
  1. Nov 10, 2026
    Enrolling by invitation→Completed
    Enrollment 400 (estimated)→159 (actual)
    + 2 other changes: verification date and date precision

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT05165316
Lead sponsor
Rene Kahn
Responsible party
Rene Kahn (Head of Psychiatry Department, UMC Utrecht) — Sponsor-investigator
First posted
Dec 21, 2021
Start date
Dec 31, 2021
Primary completion
Feb 13, 2026
Completion
Feb 13, 2026
Last update
Nov 10, 2026

Oversight

FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Nov 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion